AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32708428 — intervention group
Group type: COMPARATOR
Intervention: Ordinary high-protein, lactose-free milkshakes (500 mL, 50 g protein)
Number of subjects: 41
Study 35996073 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.04 mg/kg) and atropine (0.02 mg/kg) intravenously
Number of subjects: 454
Study 35996073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 34590717 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125
Study 34590717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 32838813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of oral ondansetron following ED visit
Number of subjects: 0
Study 32838813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32838813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of oral ondansetron
Number of subjects: 0
Study 35029357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 35029357 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 33710724 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS II block with 30 mL 0.25% bupivacaine
Number of subjects: 90
Study 33710724 — intervention group
Group type: EXPERIMENTAL
Intervention: RIB with 30 mL 0.25% bupivacaine
Number of subjects: 90
Study 33710724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study 32917171 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet use among the elderly
Number of subjects: 669
Study 32917171 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite online activity
Number of subjects: 669
Study 32917171 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information obtained through the Internet
Number of subjects: 669
Study 32917171 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand for smart services
Number of subjects: 669
Study 32917171 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing Internet use
Number of subjects: 669
Study 616795279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 0.5 mg/kg/tpd with beta-lactam plus macrolide
Number of subjects: 106
Study 616795279 — intervention group
Group type: COMPARATOR
Intervention: Placebo with beta-lactam plus macrolide
Number of subjects: 106
Study 616795279 — intervention group
Group type: COMPARATOR
Intervention: Placebo with beta-lactam plus fluoroquinolone
Number of subjects: 106
Study 616795279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone with beta-lactam plus fluoroquinolone
Number of subjects: 106
Study 616795279 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment failure
Number of subjects: 106
Study 616795279 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 106
Study 35251297 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 80
Study 35251297 — intervention group
Group type: COMPARATOR
Intervention: Traditional open surgery
Number of subjects: 80
Study 33961943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg once daily for 6 months
Number of subjects: 125
Study 33961943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 33961943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 125
Study 32331069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 464
Study 33531062 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweep
Number of subjects: 0
Study 33531062 — intervention group
Group type: COMPARATOR
Intervention: No membrane sweep
Number of subjects: 0
Study 33531062 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sweep (from 39 weeks)
Number of subjects: 0
Study 33531062 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sweep (from 40 weeks)
Number of subjects: 0
Study 33531062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single sweep
Number of subjects: 0
Study 33531062 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly sweep
Number of subjects: 0
Study 36078243 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 consecutive night shifts
Number of subjects: 73
Study 36078243 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 consecutive night shifts
Number of subjects: 73
Study 36078243 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 consecutive night shifts
Number of subjects: 73
Study 36078243 — intervention group
Group type: COMPARATOR
Intervention: Recovery days
Number of subjects: 73
Study 34033621 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg·kg‐1)
Number of subjects: 23
Study 34033621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 33739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion messaging
Number of subjects: 655
Study 33739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional messaging
Number of subjects: 655
Study 33739424 — intervention group
Group type: COMPARATOR
Intervention: Image-only control
Number of subjects: 655
Study 33077866 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Number of subjects: 43
Study 32114063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling (UGN) combined with corticosteroid injection
Number of subjects: 82
Study 32114063 — intervention group
Group type: COMPARATOR
Intervention: High-energy extracorporeal shock wave therapy (ESWT)
Number of subjects: 82
Study 34394778 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) exercise
Number of subjects: 40
Study 34394778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 32022662 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic noise exposure
Number of subjects: 12963
Study 32022662 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to traffic without disturbing noise
Number of subjects: 12963
Study 34081073 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (4200 mg)
Number of subjects: 1175
Study 34081073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study 33550815 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 65
Study 33550815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34265569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E + C supplementation
Number of subjects: 295
Study 34265569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 32937620 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated posture during a simulated workday of prolonged sitting for 7.5 hours
Number of subjects: 25
Study 32937620 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture during a simulated workday of prolonged sitting for 7.5 hours
Number of subjects: 25
Study 32937620 — intervention group
Group type: COMPARATOR
Intervention: Seated posture versus supine posture
Number of subjects: 25
Study 32937620 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated posture
Number of subjects: 25
Study 35897052 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of biologic disease-modifying antirheumatic drugs (bDMARDs)
Number of subjects: 0
Study 35897052 — intervention group
Group type: COMPARATOR
Intervention: Gradual reduction of bDMARD dosage by 50% every 3 months up to complete stop
Number of subjects: 0
Study 34387411 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira (max. dose 50 U degludec/1.8 mg liraglutide)
Number of subjects: 453
Study 34387411 — intervention group
Group type: COMPARATOR
Intervention: degludec (max. 50 U/day)
Number of subjects: 453
Study 32986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; immediate postoperative weightbearing and ankle motion.
Number of subjects: 86
Study 32986466 — intervention group
Group type: COMPARATOR
Intervention: Control group; immobilization in a below‐knee plaster cast for 2 weeks.
Number of subjects: 86
Study 32986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; tendon elongation at 2 weeks: 1.88 cm (mean side‐to‐side difference).
Number of subjects: 86
Study 32986466 — intervention group
Group type: COMPARATOR
Intervention: Control group; tendon elongation at 2 weeks: 0.71 cm (mean side‐to‐side difference).
Number of subjects: 86
Study 32986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM) group; mean Achilles tendon elongation at 1 year: 1.73 (1.07) cm.
Number of subjects: 86
Study 32986466 — intervention group
Group type: COMPARATOR
Intervention: Control group; mean Achilles tendon elongation at 1 year: 1.67 (0.92) cm.
Number of subjects: 86
Study 36071456 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-learning intervention
Number of subjects: 46
Study 36071456 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional learning)
Number of subjects: 46
Study 33618669 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-intensity 3-month targeted kyphosis exercise and posture training intervention
Number of subjects: 101
Study 32467502 — intervention group
Group type: COMPARATOR
Intervention: NOACs (dabigatran, rivaroxaban, apixaban)
Number of subjects: 13698
Study 32467502 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 13698
Study 32467502 — intervention group
Group type: COMPARATOR
Intervention: NOACs vs Warfarin
Number of subjects: 13698
Study 32467502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 13698
Study 35947391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior diagnosis in a higher diagnostic class
Number of subjects: 149
Study 35947391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior diagnosis in a lower diagnostic class
Number of subjects: 149
Study 35947391 — intervention group
Group type: COMPARATOR
Intervention: No prior diagnostic information (control)
Number of subjects: 149
Study 32918827 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisto and Ladders version 2 game
Number of subjects: 275
Study 32918827 — intervention group
Group type: COMPARATOR
Intervention: Snakes and Ladders game
Number of subjects: 275
Study 34942679 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub followed by povidone-iodine paint (Group B)
Number of subjects: 251
Study 34942679 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine paint only (Group A)
Number of subjects: 251
Study 33719027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC) 1000 mg/day
Number of subjects: 0
Study 33719027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC) 500 mg/day
Number of subjects: 0
Study 33719027 — intervention group
Group type: COMPARATOR
Intervention: Sodium ferrous citrate (SF) 100 mg/day
Number of subjects: 0
Study 32539787 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based worksite intervention utilizing pedometers, group competition, goal setting, and other incentives.
Number of subjects: 398
Study 32539787 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention applied.
Number of subjects: 398
Study 35984992 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based nudges (Conversation Connect) to promote early serious illness conversations (SICs)
Number of subjects: 79
Study 33711390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study 33711390 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anesthesia
Number of subjects: 40
Study 33711390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane treatment in H9C2 cells
Number of subjects: 40
Study 33711390 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-regulation of THAP11
Number of subjects: 40
Study 33068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating SHBG concentrations
Number of subjects: 67358
Study 35320644 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 524
Study 35320644 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 524
Study 33810049 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa and Lippia citriodora extract (MetabolAid®)
Number of subjects: 80
Study 33810049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32699327 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically influenced telomere length (standard deviation increase)
Number of subjects: 173000
Study 35218727 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 1200
Study 35218727 — intervention group
Group type: EXPERIMENTAL
Intervention: Encounter Decision Aid (EDA)
Number of subjects: 1200
Study 35218727 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for patients)
Number of subjects: 1200
Study 35218727 — intervention group
Group type: COMPARATOR
Intervention: Usual care (for clinicians)
Number of subjects: 1200
Study 32071117 — intervention group
Group type: EXPERIMENTAL
Intervention: POWER-remote
Number of subjects: 96
Study 32071117 — intervention group
Group type: COMPARATOR
Intervention: self-directed
Number of subjects: 96
Study 35937673 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved surgical eight-step washing technique
Number of subjects: 800
Study 35937673 — intervention group
Group type: COMPARATOR
Intervention: Traditional seven-step washing technique
Number of subjects: 800
Study 35937673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 800
Study 33630435 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (0-30 days after diagnosis)
Number of subjects: 80086
Study 33630435 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (90-120 days after diagnosis)
Number of subjects: 80086
Study 35341944 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of Longevity™, a proprietary essential oil blend
Number of subjects: 40
Study 35341944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 450 mg
Number of subjects: 70
Study 33624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 150 mg
Number of subjects: 70
Study 33624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv (highest peak plasma concentration quartile, Cmax > 3.29 μg/mL)
Number of subjects: 70
Study 33624184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32304404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactics to Optimize the Potential
Number of subjects: 128
Study 32304404 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study 33920894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified MI-counseling by occupational health physician and health coach (4 telephone counseling sessions)
Number of subjects: 34
Study 33920894 — intervention group
Group type: COMPARATOR
Intervention: Usual hypertension counseling
Number of subjects: 34
Study 32535124 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute decline in estimated glomerular filtration rate (eGFR)
Number of subjects: 3715
Study 32535124 — intervention group
Group type: COMPARATOR
Intervention: Evidence of decongestion (declines in BNP, NT-proBNP, or weight; increases in hematocrit, albumin, or total protein)
Number of subjects: 3715
Study 35724774 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg avasopasem
Number of subjects: 0
Study 35724774 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg avasopasem
Number of subjects: 0
Study 35724774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35724774 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasopasem (both dosages)
Number of subjects: 0
Study 33716121 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic suspension allograft (ASA)
Number of subjects: 200
Study 33716121 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 200
Study 33716121 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 200
Study 35021936 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed version of distributed practice
Number of subjects: 44
Study 35021936 — intervention group
Group type: COMPARATOR
Intervention: Extended version of distributed practice
Number of subjects: 44
Study 35021936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 34399062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440
Study 34399062 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 440
Study 32170634 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + Cyclophosphamide (TC) for 6 cycles (TC6)
Number of subjects: 195
Study 32170634 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil + Epirubicin + Cyclophosphamide followed by Docetaxel (FEC-TC)
Number of subjects: 195
Study 32170634 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by Fluorouracil + Epirubicin + Cyclophosphamide (TC-FEC)
Number of subjects: 195
Study 32170634 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 195
Study 36415191 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels on the 1st day after surgery
Number of subjects: 90
Study 36415191 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels on the 3rd day after surgery
Number of subjects: 90
Study 36415191 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, body mass index, knee flexion position, serum NETs and sVCAM-1 levels at 1 and 3 days after operation
Number of subjects: 90
Study 36415191 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum NETs and sVCAM-1 levels at 1 and 3 days after operation
Number of subjects: 90
Study 36415191 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NETs and sVCAM-1 levels at 1 day after operation
Number of subjects: 90
Study 33245589 — intervention group
Group type: COMPARATOR
Intervention: High-frequency telephone continuing care (10 contacts)
Number of subjects: 240
Study 33245589 — intervention group
Group type: COMPARATOR
Intervention: High-frequency text message continuing care (10 contacts)
Number of subjects: 240
Study 33245589 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency telephone continuing care (3 contacts)
Number of subjects: 240
Study 33245589 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency text message continuing care (3 contacts)
Number of subjects: 240
Study 33245589 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (1 contact)
Number of subjects: 240
Study 36283851 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy button securement device
Number of subjects: 0
Study 36283851 — intervention group
Group type: COMPARATOR
Intervention: Tic-tac-toe dressing
Number of subjects: 0
Study 34089409 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Number of subjects: 98
Study 34089409 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care
Number of subjects: 98
Study 32514007 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated Consult
Number of subjects: 82
Study 32514007 — intervention group
Group type: COMPARATOR
Intervention: Standard Consult
Number of subjects: 82
Study 35323633 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Exercise (TRE)
Number of subjects: 17
Study 35323633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Exercise with Blood Flow Restriction (LIRE-BFR)
Number of subjects: 17
Study 32129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention improving access to rapid diagnostic testing (RDT) through community health workers (CHWs)
Number of subjects: 0
Study 32129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience and knowledge about RDT and experience with CHWs
Number of subjects: 0
Study 32129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted use of ACTs and taking the correct dose, in addition to experience with RDT
Number of subjects: 0
Study 33574146 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with hypothermia
Number of subjects: 1330
Study 33574146 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 1330
Study 33574146 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 1330
Study 33574146 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic neonates
Number of subjects: 1330
Study 33234634 — intervention group
Group type: EXPERIMENTAL
Intervention: GR1501 (IL-17A targeted monoclonal antibody)
Number of subjects: 226
Study 33234634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 36215959 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Informed Hatha Yoga + Dialectical Behavior Therapy for Substance Use Disorders (DBT‐S)
Number of subjects: 39
Study 36215959 — intervention group
Group type: COMPARATOR
Intervention: Dialectical Behavior Therapy for Substance Use Disorders (DBT‐S)
Number of subjects: 39
Study 34740845 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study 34740845 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH MAC laryngoscope
Number of subjects: 120
Study 34740845 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐MAC laryngoscope
Number of subjects: 120
Study 36174143 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 47
Study 36174143 — intervention group
Group type: COMPARATOR
Intervention: Moderate nicotine content (MNC) cigarettes
Number of subjects: 47
Study 32415555 — intervention group
Group type: EXPERIMENTAL
Intervention: CB 2nd
Number of subjects: 116
Study 32415555 — intervention group
Group type: COMPARATOR
Intervention: PVAC Gold
Number of subjects: 116
Study 32709643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital continuous positive airway pressure (CPAP)
Number of subjects: 77
Study 32709643 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 77